The European Commission (EC) has already approved Valneva’s chikungunya vaccine Ixchiq for use in individuals aged 18 years ...

The EMA's human medicines committee has recommended approval for Bavarian Nordic's chikungunya vaccine, which is shaping up to be the first alternative to a rival shot from Valneva. The CHIKV VLP ...

Valneva has bolstered its vaccines pipeline ... known for its COVID-19 jab and recent approval for the world's first chikungunya vaccine Ixchiq – is paying €10 million upfront for a stake ...

Vaccine specialist Valneva has picked up an approval from the MHRA, as well. The agency approved the company's chikungunya vaccine, Ixchiq, for use in people 18 years of age and older. Late-stage ...

In a report released on February 12, Justine Telliez from Kepler Capital maintained a Buy rating on Valneva (0OB3 – Research Report), with a ...

Chikungunya infections began to increase by the end of September 2022 in Paraguay, which declared on Feb. 24 that it was on alert due to the “atypical clinical and epidemiological behavior” of ...

When you arrive at this page, you should enter the username and password login details provided by Worldpay in the email from [email protected]: On this page, you will be able to cancel your ...